This Phase II/III study is being conducted to determine the efficacy and safety of dapsone and atovaquone as PCP prophylactic agents for HIV infected patients who are at high risk for PCP and who are trimethoprim and/or sulfonamide intolerant.
|Effective start/end date||1/10/95 → 30/09/96|
- National Center for Research Resources
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.